Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 1.00 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31627592 | 1.00 | P2RX7 (1.00) | P2RX7GRM4KDM4EMPOCYP1A2 | |
| SCHEMBL28525840 | 0.84 | P2RX7 (0.71) | P2RX7GRM4KDM4EMPOCYP1A2 | |
| SCHEMBL37633 | 0.82 | P2RX7 (0.69) | P2RX7GRM4ADORA3GSK3AGSK3B | |
| SCHEMBL5160553 | 0.81 | P2RX7 (0.68) | P2RX7GRM4KDM4EMPOCYP1A2 | |
| SCHEMBL3650483 | 0.80 | P2RX7 (0.67) | P2RX7GRM4GSK3AGSK3BFAAH | |
| SCHEMBL17844425 | 0.79 | P2RX7 (0.66) | P2RX7GRM4KDM4EFAAHGAA | |
| SCHEMBL13729260 | 0.79 | P2RX7 (0.66) | P2RX7GRM4HTTKMT2A | |
| SCHEMBL13726856 | 0.78 | GRM4 (0.66) | P2RX7GRM4KDM4ECYP3A4GAA | |
| Hydrochloric Acid SCHEMBL30402220 | 0.78 | P2RX7 (0.65) | P2RX7GRM4GSK3AGSK3BFAAH | |
| SCHEMBL30822602 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835442-B2 | 3-substituted 7-imino-2-thioxo-3, 7-dihydro-2H-thiazolo [4,5-di pyrimidin-6-yl—and process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-09-16 | — | — | US | claimed |
| EP-2501706-B1 | A NOVEL 3-SUBSTITUTED 7-IMINO-2-THIOXO-3, 7-DIHYDRO-2H-THIAZOLO [4,5-DI PYRIMIDIN-6-YL - AND PROCESS FOR PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2014-08-06 | — | — | EP | claimed |
| WO-2011061754-A9 | A NOVEL 3-SUBSTITUTED 7-IMINO-2-THIOXO-3, 7-DIHYDRO-2H-THIAZOLO [4,5-DI PYRIMIDIN-6-YL - AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-07-05 | — | — | WO | claimed |
| US-12325702-B2 | ATF6 inhibitors and uses thereof | ALTOS LABS, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| CN-119060036-A | ATF6 inhibitors and uses thereof | 阿尔托斯实验室公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-112313224-B | ATF6 inhibitors and uses thereof | 阿尔托斯实验室公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4126869-B1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAMS | HOFFMANN LA ROCHE (CH) | 2024-06-05 | — | — | EP | disclosed |
| US-20240124434-A1 | ATF6 INHIBITORS AND USES THEREOF | ALTOS LABS, INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4139310-B1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| CN-117642404-A | Small molecule modulators of glucocerebrosidase activity and uses thereof | 凡况生化公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117580831-A | GRK2 inhibitors and uses thereof | 索纳塔治疗公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-1984907-A | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-06-20 | — | — | CN | disclosed |
| CN-1894241-A | \"1, 2, 4\" oxadiazoles as modulators of metabotropic glutamate receptor-5 | ASTRAZENECA AB (SE) | 2007-01-10 | — | — | CN | disclosed |
| EP-1723144-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-22 | — | — | EP | disclosed |
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| WO-2006014185-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-02-09 | — | — | WO | disclosed |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
| EP-1529045-A2 | NEW COMPOUNDS | Astra Zeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040152699-A1 | Compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004014881-A2 | '1,2,4'OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRA ZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124434-A1 | ATF6 INHIBITORS AND USES THEREOF | ATF4, XBP1, ATF1 | P2RX7 3653/4885GRM4 2985/4885KDM4E 4305/4885 |
| US-20040152699-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | P2RX7 1324/4885GRM4 3906/4885KDM4E 3749/4885 |
| US-12325702-B2 | ATF6 inhibitors and uses thereof | ATF4, XBP1, ATF1 | P2RX7 3653/4885GRM4 2985/4885KDM4E 4305/4885 |
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | GRM5, GRIK5, GRM1 | P2RX7 256/4885GRM4 7/4885KDM4E 2792/4885 |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | P2RX7 376/4885GRM4 12/4885KDM4E 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.